-
BMN 673: Spliceosome-Driven PARP Inhibitor Sensitivity
2026-09-24
BMN 673 (Talazoparib) is a potent PARP1/2 inhibitor for studying DNA repair vulnerabilities. This article examines how spliceosome regulation may create PARP inhibitor sensitivity in hepatocellular carcinoma—and how to test that idea without assuming evidence for one inhibitor automatically applies to another.
-
SC 79: Reading Akt Across Disease Models
2026-09-23
SC 79 offers a distinctive way to probe Akt activation in the cytosol. This article connects its mechanistic profile to neuroprotection research and a recent ovarian cancer study, while outlining practical controls and the limits of cross-domain translation.
-
Carboplatin Resistance: From DNA Damage to Stemness
2026-09-23
Carboplatin is more than a cytotoxic benchmark: it is a translational probe for connecting DNA damage, cancer stem-cell biology, RNA regulation, and treatment resistance. This article outlines how the IGF2BP3–FZD1/7 axis may reshape Carboplatin study design in preclinical oncology research and how researchers can build more informative combination and biomarker strategies.
-
Annexin V-PE Apoptosis Detection Kit Guide
2026-09-22
A scenario-based guide to using the Annexin V-PE Apoptosis Detection Kit, SKU K2200, for rapid phosphatidylserine externalization analysis in live-cell research. It covers assay principles, workflow compatibility, protocol controls, interpretation limits, and practical product-selection criteria.
-
Cyanidin Chloride: An Assay-First Redox Guide
2026-09-22
Cyanidin Chloride is an anthocyanin polyphenolic antioxidant for structured oxidative stress research. This guide adds an identity-aware assay framework that separates radical chemistry, cellular protection, inflammatory signaling, and epithelial barrier outcomes.
-
RIPA Lysis Buffer (Medium): Build a Causal Evidence Chain
2026-09-21
RIPA Lysis Buffer (Medium) can convert complex cell and tissue responses into interpretable protein evidence. This guide shows how its detergent chemistry, inhibitor strategy, and assay-specific controls can strengthen mechanistic analysis of MRSA extracellular-vesicle signaling in oral cancer models.
-
CUDC-907: Dual PI3K/HDAC Workflow Guide
2026-09-21
CUDC-907 is a dual PI3K and HDAC inhibitor for controlled in vitro studies of signaling, acetylation, cell-cycle behavior, and apoptosis. This guide uses product-dossier specifications and practical laboratory recommendations; the compound is for scientific research only and should not be used for diagnosis, treatment, or clinical decision-making.
-
Doxorubicin Hydrochloride: Assays & Cardiotoxicity
2026-09-20
Build reproducible cancer chemotherapy research and cardiotoxicity workflows with Doxorubicin hydrochloride, from dose–response and apoptosis assays to mechanistic energy-stress studies. A practical workflow connects Adriamycin HCl exposure with the emerging KLF16–ATF4–CSE/H2S antioxidation axis while separating established evidence from assay-development recommendations.
-
Methotrexate Workflows for Immunology Research
2026-09-19
Build reproducible Methotrexate experiments around DHFR inhibition, exposure timing, and orthogonal readouts of cytostasis, apoptosis, and inflammation. This workflow distinguishes direct cellular effects from vehicle, folate-state, and assay-timing artifacts while connecting bench immunology to clinically relevant mechanisms.
-
GLI2–PRDX1 Axis Drives Ferroptosis Resistance
2026-09-18
The 2026 reference study identifies GLI2 as a transcriptional driver of ferroptosis resistance in bladder cancer through upregulation of PRDX1. Its perturbation, chromatin, transcriptomic, and rescue experiments connect this axis to malignant progression and cisplatin sensitivity, providing a mechanistic framework for chemotherapy-oriented cancer research.
-
Ibotenic Acid: NMDA Agonist Workflow Guide
2026-09-18
This practical guide shows how to use Ibotenic acid as a controlled neuroscience research tool for glutamatergic signaling studies, neurotoxicity profiling, and neurodegenerative disease model development. It translates recent dose- and time-dependent mouse findings into assay planning, sample handling, and troubleshooting decisions.
-
Amyloid β-Peptide (1-42): Microglial Assays
2026-09-17
Use Amyloid β-Peptide (1-42) to build two complementary Alzheimer’s disease models: a neuronal injury assay and a microglial migration, uptake, and clearance workflow. The key advantage is mechanistic resolution—aggregation state, extracellular nucleotide signaling, and P2Y2-dependent Aβ42 handling can be tested separately rather than treated as one nonspecific toxicity endpoint.
-
Palonosetron and Chemotherapy-Induced Nausea
2026-09-17
Ruhlmann and Herrstedt’s drug profile examines whether palonosetron’s distinctive receptor pharmacology translates into better prevention of chemotherapy-induced nausea and vomiting than earlier 5-HT3 antagonists. Its practical contribution is a structured comparison of preclinical evidence, registration trials, and post-registration experience, with particular attention to acute versus delayed symptoms, nausea control, and tolerability.
-
Dacarbazine in Cancer Response Assays
2026-09-16
Use Dacarbazine to model DNA-damaging chemotherapy in malignant melanoma, Hodgkin lymphoma, and sarcoma research while separating growth arrest from true cell killing. This workflow combines controlled exposure, orthogonal viability measurements, and time-aware interpretation to produce more informative response profiles than a single endpoint.
-
Cholesterol Workflows for mRNA-LNP Research
2026-09-16
Learn how Cholesterol supports reproducible lipid nanoparticle assembly, membrane fluidity assays, and localized mRNA delivery research. This workflow translates bladder cancer findings into practical formulation, quality-control, and troubleshooting steps while distinguishing published evidence from experimental starting points.